For the quarter ended March 2026, Mirum Pharmaceuticals, Inc. (MIRM Quick QuoteMIRM - Free Report) reported revenue of $159.88 million, up 43.3% over the same period last year. EPS came in at -$0.39, compared to -$0.30 in the year-ago quarter.

The reported revenue compares to the Zacks Consensus Estimate of $148.04 million, representing a surprise of +8%. The company delivered an EPS surprise of +3.47%, with the consensus EPS estimate being -$0.40.

While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.

As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.

Here is how Mirum Pharmaceuticals performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

• Product Sales- Livmarli: $113.8 million compared to the $104.83 million average estimate based on three analysts.
• Total product sales, net: $159.88 million versus the three-analyst average estimate of $146.86 million.
• Product Sales- Bile Acid Medicines: $46.08 million compared to the $42.06 million average estimate based on three analysts.

View all Key Company Metrics for Mirum Pharmaceuticals here>>>

Shares of Mirum Pharmaceuticals have returned +10.6% over the past month versus the Zacks S&P 500 composite's +10.3% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.